Effectiveness and Adverse-effect Switch Evaluation

Bristol-Myers Squibb

Summary

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Participants (or caregiver/legal guardian) must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines. * Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up. * Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride…

Interventions

Drug
Xanomeline and trospium chloride (KarXT)
According to the product label

Locations (45)

Local Institution - 0009
Bryant, Arkansas
Local Institution - 0003
Anaheim, California
Local Institution - 0039
Chino, California
Local Institution - 0012
La Palma, California
Local Institution - 0043
Oceanside, California
Local Institution - 0028
Stanford, California